What I learned at Global Access 2026
Notes from the sessions I sat in at Global Access in Galway. These are my takeaways, not a transcript.
MDR and IVDR reform
Certification has become slower and more expensive, especially for smaller companies. Speakers argued that this is holding back patient access and pushing innovation elsewhere.
The ideas on the table included reviews triggered by evidence and not by the calendar, more use of real-world evidence and computational methods, adaptive routes for breakthrough, AI, orphan and paediatric devices, and joined-up early scientific advice for SMEs.
The practical message was to keep meeting today's deadlines while reform works its way through. How far simplification should go is still being argued over.
Regulators relying on each other
The UK plans to keep recognising the CE mark, with reliance routes planned for Australian, Canadian and US approvals. Sandboxes for AI and software, and early-access routes, were presented as ways to build real-world evidence.
The thread running through every regulator's talk was oversight across the whole life of a device. That means confidence in post-market data, quality systems and shared adverse-event terminology, as well as the pre-market review.
The EU's proposed changes would formalise international cooperation and reliance, and Health Canada is exploring a reliance tool within its existing licensing process.
Regulation moves quickly. Check the current position before relying on any of this.